Compounds > letrozole

letrozole and spironolactone

letrozole has been researched along with spironolactone in 11 studies

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (9.09)	29.6817
2010's	2 (18.18)	24.3611
2020's	8 (72.73)	2.80

Authors

Authors	Studies
Andricopulo, AD; Moda, TL; Montanari, CA	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Adeyanju, OA; Fabunmi, OA; Falodun, TO; Olatunji, LA; Soladoye, AO	1
Adeyanju, OA; Agbana, RD; Falodun, TO; Michael, OS; Oyewole, AL; Soetan, OA	1
Adeyanju, OA; Ojulari, LS; Olaiya, OE; Olaniyi, KS; Omoaghe, AO; Oniyide, AA	1
Dehghan, Z; Mirmotalebisohi, SA; Mohammadi-Yeganeh, S; Salehi, M; Sameni, M; Zali, H	1
Brady, PH; Gin, GT; Rosenblum, E; Wilkinson, LD	1
Akintayo, CO; Areloegbe, SE; Aturamu, A; Olaniyi, KS; Oniyide, AA; Peter, MU	1
Chen, R; Lin, X; Yang, X; Yuan, X; Zhang, Y	1
Areloegbe, SE; Olaniyi, KS; Oyeleke, MB; Peter, MU	1
Agbana, RD; Ajadi, IO; Areloegbe, SE; Areola, ED; Atuma, CL; Fafure, AA; Olaniyi, KS; Olatunji, LA; Sabinari, IW; Shah, MZUH	1

Reviews

1 review(s) available for letrozole and spironolactone

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

10 other study(ies) available for letrozole and spironolactone

Article	Year
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone. Chemico-biological interactions, 2019, Sep-01, Volume: 310 Topics: Androgen Antagonists; Animals; Female; Insulin Resistance; Letrozole; Luteinizing Hormone; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Rats; Rats, Wistar; Spironolactone; Testosterone	2019
Spironolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: tissue uric acid-a familiar foe. Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:6 Topics: Animals; Female; Letrozole; Liver; Ovary; Polycystic Ovary Syndrome; Rats; Rats, Wistar; Spironolactone; Triglycerides; Uric Acid	2020
Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS. Toxicology and applied pharmacology, 2021, 01-15, Volume: 411 Topics: Adiponectin; Animals; Biomarkers; Disease Models, Animal; Female; Inflammation Mediators; Letrozole; Lipids; Mineralocorticoid Receptor Antagonists; Ovarian Follicle; Ovary; Polycystic Ovary Syndrome; Prolactin; Rats, Wistar; Spironolactone; Testosterone	2021
Repurposing new drug candidates and identifying crucial molecules underlying PCOS Pathogenesis Based On Bioinformatics Analysis. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2021, Volume: 29, Issue:2 Topics: Computational Biology; Databases, Protein; Drug Repositioning; Female; Gene Expression Regulation; Humans; Letrozole; Metformin; Phosphatidylinositol 3-Kinases; Pioglitazone; Polycystic Ovary Syndrome; Protein Interaction Maps; Proteomics; Proto-Oncogene Proteins c-akt; Signal Transduction; Spironolactone	2021
Female Pelvic Conditions: Polycystic Ovary Syndrome. FP essentials, 2022, Volume: 515 Topics: Acne Vulgaris; Anovulation; Female; Finasteride; Gonadotropin-Releasing Hormone; Hirsutism; Humans; Hyperandrogenism; Infertility; Letrozole; Male; Obesity; Polycystic Ovary Syndrome; Spironolactone; Weight Loss	2022
Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model. Canadian journal of physiology and pharmacology, 2022, Sep-01, Volume: 100, Issue:9 Topics: Animals; bcl-2-Associated X Protein; Disease Models, Animal; Female; Humans; Inflammasomes; Letrozole; Polycystic Ovary Syndrome; Rats; Rats, Wistar; Spironolactone	2022
Long-Term Treatment With Letrozole in a Boy With Familial Male-Limited Precocious Puberty. Frontiers in endocrinology, 2022, Volume: 13 Topics: Adult; Child; Child, Preschool; Humans; Letrozole; Male; Puberty, Precocious; Spironolactone; Triptorelin Pamoate	2022
Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model. BMC endocrine disorders, 2022, Sep-07, Volume: 22, Issue:1 Topics: Adipose Tissue; Animals; Apoptosis; Female; Humans; Inflammation; Letrozole; Polycystic Ovary Syndrome; Rats; Rats, Wistar; Spironolactone	2022
Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome. Toxicology and applied pharmacology, 2023, Aug-15, Volume: 473 Topics: Animals; Dyslipidemias; Female; Humans; Inflammation; Letrozole; NLR Family, Pyrin Domain-Containing 3 Protein; Polycystic Ovary Syndrome; Proprotein Convertase 9; Rats; Rats, Wistar; Receptors, LDL; Spironolactone	2023